Zealand Pharma
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 50 / 2024
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, November 11, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached file(s).
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about the company's business and activities, please visit www.zealandpharma.com.
Contact:
Adam Lange Investor Relations Officer Email: akl@zealandpharma.com Neshat Ahmadi Investor Relations Manager Email: nea@zealandpharma.com Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Email: ank@zealandpharma.com |
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Financière de Tubize SA2.8.2025 08:00:00 CEST | Press release
Financière de Tubize - 2025 half-year financial report
DBV Technologies S.A.1.8.2025 22:05:00 CEST | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Mandalay Resources Corporation1.8.2025 21:12:01 CEST | Press release
Mandalay Obtains Final Order Approving Arrangement with Alkane
F. Hoffmann-La Roche Ltd1.8.2025 20:00:00 CEST | Press release
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
KBC Groep1.8.2025 18:10:00 CEST | Press release
KBC Group: KBC remains well-capitalised under 2025 EU-wide EBA stress test
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom